secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001493152-23-000906
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical appoints Mark Schallenberger as COO effective Jan 16, 2023
------------------------------------------------------------------------

- Mark Schallenberger, previously COO at Surgenex, appointed COO at Xtant Medical effective Jan 16, 2023.
- Annual base salary of $400,000 with bonus of up to 50% of base salary; option for 105,000 shares and RSUs for 89,000 shares.
- Role is newly created, focused on operational modernization and product development.
- Previously served at Xtant (formerly Bacterin) as Director of Scientific Affairs from 2010-2016.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223000906/0001493152-23-000906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223000906/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer